← Leaderboards
Jeffrey Reich
Sparian Biosciences, Inc.
$28,894,251
Attributed
$28,894,251
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8M · FY2021–25$10M$7.5M$5M$2.5M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,894,251 · 4
By mechanism
UG3$14,845,721 · 2
UH3$13,729,307 · 1
R44$319,223 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Oral”
- Yunda Huang · Fred Hutchinson Cancer Center$53,780,853
- Susan Abushakra · Alzheon, Inc.$50,765,244
- John Damon Chodera · Sloan-Kettering Inst Can Research$40,061,627
- Gary Fanger · Rise Therapeutics, Llc$23,676,385
- James Dale Berry · Brigham And Women'S Hospital$15,344,018
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$14,320,275
Research focus
OralSafetyEpidemicDoseToxicologyPharmaceutical PreparationsOpioid EpidemicPhase I Clinical TrialsRewardsPhase 1 StudyWithdrawalOpioid UseAntagonistVentilatory DepressionOpioidMorphinePrescription OpioidDesignPersonsAbsence Of Pain SensationPainPhysical DependenceLead CandidateLead
Grant awards (8)
Development of SBS-226, a MOR agonist / DOR antagonist, for OUD$3,984,629
UG3 · FY2025 · DA · contact PI
Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder$4,017,447
UG3 · FY2024 · DA · contact PI
Development of SBS-226, a MOR agonist / DOR antagonist, for OUD$3,957,359
UG3 · FY2024 · DA · contact PI
Arylepoxamides: A new class of potent, safer analgesics$4,506,061
UH3 · FY2023 · DA · contact PI
Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder$2,886,286
UG3 · FY2023 · DA · contact PI
Arylepoxamides: A new class of potent, safer analgesics$4,628,029
UH3 · FY2022 · DA · contact PI
Arylepoxamides: A new class of potent, safer analgesics$4,595,217
UH3 · FY2021 · DA · contact PI
Development of CP-analogs as novel treatments for opioid use disorder.$319,223
R44 · FY2021 · DA · contact PI